C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
C4 Therapeutics (Nasdaq: CCCC) approved an inducement grant of non-qualified stock options to purchase 85,480 shares of common stock for one new employee, effective May 18, 2026.
The options’ exercise price equals the closing stock price on the grant date and vest over four years, subject to continued employment.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – CCCC
On the day this news was published, CCCC declined 3.42%, reflecting a moderate negative market reaction. Argus tracked a trough of -7.5% from its starting point during tracking. Our momentum scanner triggered 29 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $13M from the company's valuation, bringing the market cap to $366.53M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Pre-news, CCCC was at $3.56 while peers like ELTX (-0.56%), IPHA (-6.48%), NTHI (-2.14%), TRDA (-4.2%) and SLS (-1.12%) were mostly negative, suggesting stock-specific dynamics rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 12 | Q1 2026 earnings | Neutral | +0.0% | Quarterly results with modestly lower revenue and extended cash runway. |
| Apr 09 | Roche collaboration | Positive | -2.4% | Expanded Roche DAC deal with $20M upfront and >$1B milestones. |
| Mar 25 | Clinical trial update | Positive | +7.6% | First patient dosed in Phase 1b cemsidomide plus elranatamab trial. |
| Mar 09 | Inducement grant | Neutral | -13.1% | Inducement non-qualified stock option grant of 85,480 shares to one hire. |
| Feb 26 | FY 2025 earnings | Positive | +0.4% | Year-end results, cash runway to end of 2028 and financing update. |
News flow has triggered mixed reactions, with clinical and collaboration updates sometimes drawing sizable moves, while prior inducement grants saw a double-digit decline despite their small, HR-driven nature.
Over recent months, C4 Therapeutics reported earnings, expanded a major Roche collaboration, advanced cemsidomide into Phase 1b/2 trials, and issued a similar inducement option grant of 85,480 shares on Mar 9, 2026. Price reactions ranged from a 7.6% gain on a Phase 1b dosing update to a -13.09% move after the prior inducement grant. Today’s grant mirrors that structure, fitting within ongoing hiring and compensation activity alongside pipeline and partnership execution.
Regulatory & Risk Context
The company has an effective S-3 shelf filed on 2025-11-21 to offer up to $400,000,000 in various securities, including an at-the-market program for up to $125,000,000 of common stock as part of that total. As of the latest data, usage_count is 0, indicating no recorded takedowns from this shelf in the provided context.
Market Pulse Summary
This announcement details a routine inducement grant of 85,480 non-qualified stock options under Nasdaq Listing Rule 5635(c)(4), vesting over 4 years with a 25% first-year cliff and 36 monthly installments thereafter. It follows similar hiring-related equity actions seen in March 2026 and sits alongside larger strategic developments such as clinical progress and a Roche collaboration. Investors may monitor how ongoing equity compensation interacts with the existing $400,000,000 shelf capacity and overall share count over time.
Key Terms
non-qualified stock options financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. Not financial advice.
WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the grant made on May 18, 2026 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grant has an exercise price per share that is equal to the closing price of C4T’s common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
Contacts:
Investors:
Courtney Solberg
Associate Director, Investor Relations
CSolberg@c4therapeutics.com
Leah Gibson
Vice President, Investor Relations & Communications
LGibson@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
